REG - Genedrive PLC - Sussex NHS Trust transitions MT-RNR1 test to BAU

GenedriveAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260505:nRSE9073Ca&default-theme=true

RNS Number : 9073C  Genedrive PLC  05 May 2026

5 May 2026

genedrive plc

("genedrive" or the "Company")

 

University Hospitals Sussex NHS Foundation Trust transitions genedrive's
MT-RNR1 test to Business as Usual clinical service

 

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company,
is pleased to announce that, from 1 May 2026, University Hospitals Sussex NHS
Foundation Trust ("UHS") hospitals transitioned to Business as Usual ("BAU")
routine clinical service of the Genedrive® MT-RNR1 ID kit for the prevention
of Antibiotic Induced Hearing Loss ("AIHL") in neonates admitted to Neonatal
Intensive Care Units ("NICU").

 

UHS Royal County Sussex Hospital's Trevor Mann Baby Unit provides specialist
care for approximately 400 NICU admissions annually and has been a
participating site in the PALOH-UK programme, which aims to address National
Institute for Clinical Care and Excellence ("NICE") Real World Evidence
generation requirements. To date, nearly 40 babies in NICUs have been
identified with the MT-RNR1 variant since introduction of the test in the UK,
enabling alternative antibiotic prescription and reducing the risk of
aminoglycoside-induced lifelong hearing loss.

 

Dr Gino Miele, CEO of genedrive plc, said: "The transition to BAU routine
clinical service at UHS is a key milestone in driving wider scale adoption of
our MT-RNR1 genetic test in the UK. UHS was an early adopter of this test
prior to the initiation of the PALOH-UK programme and has been a key supporter
of genedrive's technology. Since its introduction in the region, the test has
had clear impact, identifying several babies who otherwise would have been at
risk of lifelong hearing loss. We are delighted that babies and families in
this region of NHS England will continue to benefit from the routine
availability of our test.

 

"We are in active discussions with other hospitals in the PALOH-UK programme
to support the transition of our MT-RNR1 test from PALOH-UK based funding to
embedding into routine practice to ensure that newborn babies across the UK
continue to have access to this preventive test."

 

Funding for PALOH-UK sites is provided by the Office for Life Sciences ("OLS")
and National Institute for Health and Care Research ("NIHR") and will cease by
June 2026, with some sites completing earlier. Subsequent review and issuance
of final guidance by NICE is expected around July 2027.

 

 

 genedrive plc
                                                                         +44 (0)161 989 0245
 Gino Miele: CEO / Russ Shaw: CFO
                                                        https://investors.genedrive.com/s/e0025c
                                                        (https://investors.genedrive.com/s/e0025c)

 Peel Hunt LLP (Nominated Adviser and Broker)
                                                                          +44 (0)20 7418 8900
 James Steel

 5654 & Company  (Media & Investor Relations)           genedrive@5654.co.uk
 Matthew Neal                                           +44 (0)7917 800 011
 Melissa Gardiner                                       +44 (0)7757 697357

 

Subscribe to our news alert service: https://investors.genedrive.com/s/efea03
(https://investors.genedrive.com/s/efea03)

 

About genedrive plc (http://www.genedrive.com (http://www.genedrive.com) ).

 

genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company
focused on rapid, point-of-care diagnostic tests to guide safe and effective
drug prescription in emergency and acute care settings.

 

genedrive's proprietary technology platform enables clinicians to prescribe
safer and more effective therapies based on a patient's genetic profile,
supporting improved outcomes while reducing pressure on healthcare systems,
lowering downstream healthcare costs through the prevention of avoidable
complications and earlier, more effective intervention

 

The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical
use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not
respond to the current standard of care, Clopidogrel, used to reduce risk of
secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent
antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment
decisions within actionable timeframes at the point of care.

 

Headquartered in Manchester, genedrive is focused on scaling UK-developed
precision diagnostics within routine care and leveraging real-world evidence
to support broader international adoption and commercial growth.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDAKQBNOBKDPPK



            Copyright 2019 Regulatory News Service, all rights reserved